HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Parlux

This article was originally published in The Rose Sheet

Executive Summary

Parlux: Board of Directors authorizes Chairman and CEO Ilia Lekach to "pursue all reasonable actions to enhance shareholder value," the company announced in a Sept. 12 statement. "The company has no knowledge of any unusual occurrence, activity or negative news which has recently placed its stock under pressure to levels well below industry standards," the statement added. Parlux noted that the "fundamental performance of the company is sound and business is currently on target to plan." On Sept. 11, the issue slid 17.1% (down 3/4) to close at 4-3/8 on NASDAQ trading volume of 4,493,000...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel